Palladium-103 plaque brachytherapy for retinoblastoma: Long term follow up

Abhilasha Maheshwari, Paul T. Finger *

Department of Ocular Tumor, Orbital Disease and Ophthalmic Radiation Therapy, The New York Eye Cancer Center, 115 East 61st Street, New York City, New York, 10065, USA

ARTICLE INFO

Keywords:
Retinoblastoma
Palladium-103
Plaque
Brachytherapy
Visual acuity
Survival

ABSTRACT

Purpose: Radiation has been used in the treatment of retinoblastoma. Herein, we present the novel use of palladium-103 plaque brachytherapy as primary treatment.

Observation: An 8-year-old asymptomatic girl presented was found to have a solitary peripheral retinoblastoma in her right eye. She was treated with primary palladium-103 plaque brachytherapy (47.4 Gray over 5 consecutive days). A secondary, vitreous hemorrhage noted 46 months after irradiation was successfully controlled by laser tumor-demarcation. With 19-years follow up, there has been no clinical scleropathy, or local tumor recurrence. The eye yields 20/20 vision and there has been no systemic metastasis.

Conclusion and importance: Palladium-103 plaque brachytherapy successfully controlled retinoblastoma, while preserving the globe, vision, and life.

1. Introduction

Retinoblastoma (RB) represents 3% of all childhood cancers and is the most common intraocular malignancy of childhood. The mean age at diagnosis is 9 months (bilateral) and 23 months (unilateral). The primary goals of management of retinoblastoma are to save life, preserve the eye, and vision.

Intravenous chemotherapy is used most widely in treatment of primary treatment for retinoblastoma. Alternatively, the American Brachytherapy Society (ABS) together with the American Association of Physicists in Medicine (AAPM) consensus guidelines suggest that plaque brachytherapy is typically used for smaller, anterior, solitary tumors. In addition, plaque has been used for select tumors, specifically for eye salvage threatened by residual or recurrent tumors. It is generally believed that plaque brachytherapy is more localized and thus less likely to induce second non-ocular cancers compared to external beam techniques.

Plaque modalities that have been previously described in literature include: cobalt-60 (60Co), iodine-125 (125I), iridium-192 (192Ir) and ruthenium-106 (106Ru). Typical radioactive plaque treatment for RB as described the ABS-AAPM consensus guidelines as well as by Munier and colleagues involves its placement onto the eye (sclera) as to cover the base of the tumor plus a margin of safety; then continuous dose in a range of 40–50 Gray (Gy) is given over 3–5 days. In a literature review utilizing the keywords retinoblastoma, palladium-103, iodine-125, ruthenium-106, plaque, brachytherapy, visual acuity, and survival; we could find no prior reported cases of RB treated with palladium-103 (103Pd) plaque brachytherapy. Herein, we present our experience treating a select, unifocal, anterior RB utilizing 103Pd plaque brachytherapy.

2. Case presentation

An 8-year-old girl was referred to The New York Eye Cancer Center for evaluation of a white retinal tumor discovered during fundus examination of an asymptomatic right eye. An only daughter of RB negative patients, her first cousin was noted to have bilateral RB. She was evaluated by clinical examination, ophthalmic imaging (photography, angiography, optical coherence tomography and ultrasound). Though available in 2004, germline RB1 mutation testing was not routinely covered and too expensive for our patient.

Ophthalmic oncology examination revealed a best corrected visual
acuity of 20/20 in both eyes. Her anterior segment, pupillary reactions and extracocular muscle movements were normal. Intraocular pressures were 20 and 17-mm Hg, respectively. There was no iris neovascularization or anterior segment manifestation of tumor. Indirect ophthalmoscopy revealed and fundus photography documented a white, fungating, irregular tumor in the supero-temporal quadrant measuring 8.5 \times 8 \text{ mm in basal diameter} (Fig. 1). Its posterior margin was measured to be 13 \text{ mm} away from the edge of the optic disc and 14 \text{ mm} from the center of the fovea. The vitreous was clear and without tumor seeding.

Fluorescein angiography showed a well-defined pattern of retinal capillaries that filled during the arterial phase and became diffusely hyperfluorescent in the later phases (Fig. 2). Optical coherence tomography revealed subretinal fluid over the surface of the tumor, less than 5 \text{ mm} from the edge of the tumor and not in the macula. High-resolution 20MHz B-scan ultrasound imaging revealed a dome-shaped tumor with highly reflective intrastromal masses yielding variable acoustic reactivity and orbital shadowing. No evidence of extraocular extension was noted. The tumors maximal thickness of was 2.8 mm (Fig. 3).

According to the most current, "8th edition” American Joint Committee on Cancer staging system for retinoblastoma the tumor would be classified a T1aN0M0 (Stage I). In consideration of our patient’s family history, MRI was the preferred method for screening our patient, but the patient and her family refused MRI in favor of computed radiographic tomography of her orbit and brain, which were negative for extraocular RB. Then informed consent led to shared decision. Her parents chose local plaque treatment to avoid side effects of systemic chemotherapy.

At treatment, a 14-mm gold plaque therapy contained 12 \text{ 103Pd} seeds (Theragenics, Buford, Georgia, USA) at 1.47 mCi/seed for a total 19.3 mCi. With prescription point at 2.8 axial mm from the inner scleral surface, the plaque duration was 5 days for a total dose of 47.4 Gy. Calculated doses (in Gy) to normal ocular structures when utilizing the \text{ 103Pd} plaque were lens center (5.4), optic disc (5.3), central fovea (4.2), opposite retina (1.4) and inner sclera (128.5), respectively (Table 1). As the dosimetry of only \text{ 103Pd} was available for review, we requested medical physics to calculate comparative dosimetry of \text{ 125I} versus \text{ 103Pd}. As Principal Investigator for the Collaborative Ocular Melanoma Study Protocol, Dr. Finger notes that doses to opposite retina, optic disc and fovea were all collected as important parameters to assess the effect of ocular irradiation, and were later found to be prognostic for secondary ischemic radiation oculopathy. The results are summarized in Table 1.

Intraoperatively, scleral transillumination was used to place episcleral markings at the tumor base and 2–3 \text{ mm} safety margin. The plaque was affixed to the eye wall over the targeted zone using interrupted 5-0 absorbable sutures (Fig. 4). Intraoperative ultrasound imaging was used to confirm proper plaque placement. The patient received continuous radiation over 5 days, after which the radioactive plaque was surgically removed.

After 46 months the tumor began to bleed into the vitreous without growth. There was no tumor growth (Fig. 5). In an effort to contain the hemorrhage, the retina posterior to the tumor residua was treated with transpupillary thermotherapy (TTT), 3 \text{ mm} spot size, laser photocoagulation at 1000 mW and 900 msec durations. The strategy was to cut off the tumor circulation, then directly treat the tumor residua and any surrounding radiation-related retinal microangiopathy.

Post-treatment periodic ophthalmic examinations included: clinical examination, fundus photography, ultrasound imaging and optical coherence tomography (OCT). Fluorescein angiography was performed every 6-months to monitor radiation related vasculopathy as well as monitor tumor regression.

Her most recent examination was 19-years after \text{ 103Pd} plaque brachytherapy.
brachytherapy. The original tumor location is an atrophic flat white scar with well-defined margins (Fig. 1). At her last ultrasound imaging measurement, there was a documented reduction of tumor thickness from the original 2.8 to 0.9 mm (a 68% decrease). There is evidence of relatively static, Finger Stage-I radiation retinopathy without maculopathy or optic neuropathy as well as 20/20 vision in the affected eye. There has been no scleropathy or metastatic disease.

3. Discussion

Each case of RB is unique; therefore, treatment regimens must be customized to maximize outcomes for varying disease presentations. In this case we chose $^{103}$Pd plaque brachytherapy as primary treatment for retinoblastoma. Irradiation caused a reduction in tumor thickness and resolution of subretinal fluid with Shield’s Type 4 regression, which is the most common regression pattern in retinoblastoma. Treatment resulted in local cancer control, vision retention and lack of metastatic disease. Tumor control was related to the use of treatment margins, lack of vitreous seeding, and the small American Joint Committee on Cancer (AJCC) tumor stage 1 (T1aN0M0). In that this retinoblastoma presented in an older child, the differential diagnosis included solitary astrocytoma (without tuberous sclerosis) and retinocytoma. This prompted a literature search where we found no cases of solitary astrocytoma in this age group. Retinocytomas are on a spectrum with retinoblastoma and are treated when active.

Retinoblastoma has been treated with $^{125}$I and $^{106}$Ru eye plaques, $^{5,6,11,28}$ Kiratli et al. used $^{125}$I as a primary procedure in 5 patients and noted no tumor recurrence or complications. $^{28}$ Shields et al. reported using a variety of radionuclides: $^{60}$Co, $^{125}$I, $^{192}$Ir and $^{106}$Ru as primary treatment for 31 cases and noted local recurrences in 16% at a follow up of 3.5 years. $^{6}$ In a later study, they reported on 60 tumors treated with $^{125}$I plaque radiotherapy, yielding a recurrence rate of 12% at 1 year. $^{11}$ Similarly, Abouzeid et al. noted a tumor recurrence in 12.5% tumors at 1 year, when $^{106}$Ru plaque brachytherapy was used as a first- or second-line treatment. $^{8}$ Lastly, Amendola et al. also used various plaques $^{60}$Co, $^{125}$I, $^{192}$Ir and $^{106}$Ru with a recurrence in 17% at 2 years. $^{10}$ Clearly, local plaque therapy can avoid exposure to and potential complications from common systemic chemotherapy treatments that include 6-cycles (1 month apart) of carboplatin 500 mg/m$^2$ on day 1, vincristine 1.50 mg/m$^2$ on day 1 and etoposide 150 mg/m$^2$ on days 1 and 2. $^{4}$ However, due to variable and specifically multifocal presentations of RB, plaque use has been limited.

Current indications for the use of plaque therapy in cases of retinoblastoma include solitary RB where plaque treatment offers less side effects and an improved prognosis for vision. $^{5}$ Other common plaque brachytherapy indications include: globe salvage due to a recurrent tumor following EBRT, secondary treatment for medium sized chemotherapy-resistant tumors (< 16 mm diameter and 3–9 mm thickness) with or without localized vitreous or sub retinal seeding, and following recurrence after IVC or IAC. $^{4,23,29,30}$

Though, retinoblastoma tends to be radiation sensitive, RB in late childhood can be quite different in presentation and resistant to focal therapy (compared to RB in children less than 5-years of age). $^{31}$ The strengths of this unique $^{103}$Pd plaque study include the use of a radiation source that (for an equivalent dose to the tumor’s apex), delivered a greater dose to the tumors base and thereby increased the amount of
radiation delivered within the retinoblastoma. At the same time, due to the relatively rapid absorption of $^{103}$Pd radiation within the vitreous, less radiation reached the visually important fovea and optic nerve compared to the more commonly used $^{125}$I (Table 1). Though these actual doses to these vision critical structures may have been low in this case, the option to use $^{103}$Pd and pre-operative comparative dosimetry offers a potential method to improve outcomes. In this case, when comparing $^{103}$Pd vs $^{125}$I, the higher measured dose to the tumor cannot be correlated to improved local control, nor can the reductions in fovea and optic disc to vision retention without a case-matched control. However, these differences need be reported for later study.

While posterior segment complications were not expected at the calculated doses, cataract was anticipated due to the anterior location of the tumor and corresponding radiation dose to the natural lens. Other than the transient vitreous hemorrhage which resolved after laser demarcation of the tumor, there were no visually significant radiation side effects. Lastly, this report uniquely includes a rare 19-year-post-plaque follow up experience.

In conclusion, this report suggests that BB may be successfully treated with $^{103}$Pd plaque brachytherapy yielding tumor control, with preservation of both life and vision.

Patient consent

The patient consented to publication of the case in writing. This report does not contain any personal information that could lead to the identification of the patient. Therefore, the case conforms to the Tenet’s of Declaration of Helsinki and the Health Insurance Privacy and Portability Act. It has been approved for publication by The New York Eye Cancer Center’s IRB and Ethics committee.

Intellectual property

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication with respect to intellectual property. In doing so we confirm that we followed the regulations of our institutions concerning intellectual property.

Research ethics

We further confirm that any aspects of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

Funding

This research was supported by The Eye Cancer Foundation http://eye cancercure.com.

Declaration of competing interest

Dr. Finger is the Chief Executive Officer of LV Liberty Vision Corporation https://libertyvision.com.

Authorship

All authors attest that they meet the current ICMJE criteria for authorship.

Acknowledgments

The authors acknowledge the medical physicist Yong Hum Na, PhD for calculating the relative $^{125}$I doses.

References

1. Mallipatna AC, Gallie BL, Chevez-Barrios P, et al. Retinoblastoma. (Chapter 68). In: Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual. eighth ed. Springer International Publishing; 2016:827–839.
2. Tomar AS, Finger PT, Gallie B, et al. A multicenter, international collaborative study for American Joint Committee on cancer staging of retinoblastoma: Part I: metastasis-associated mortality. Ophthalmology. 2020;127(12):1719–1732.
3. Tomar AS, Finger PT, Gallie B, et al. A multicenter, international collaborative study for American Joint Committee on cancer staging of retinoblastoma: Part II: treatment success and globe salvage. Ophthalmology. 2020;127(12):1733–1746.
4. Rao R, Honavar SG. Retinoblastoma. Indian J Pediatr. 2017;84(12):979–994.
5. American Brachytherapy Society - Ophthalmic Oncology Task Force., ABS – OOTT Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14.
6. Shields CL, Shields JA, De Potter P, et al. Plaque radiotherapy in the management of retinoblastoma. Use as a primary and secondary treatment. Ophthalmology. 1993;100(2):216–224.
7. Rodjan F, Graaf P de, Brisse HJ, et al. Second cranio-facial malignancies in hereditary retinoblastoma survivors previously treated with radiation therapy: clinic and radiologic characteristics and survival outcomes. Eur J Cancer. 2013;49(8):1939–1947.
8. Abouzeid H, Moeckli R, Gaillard MC, et al. (106)Ruthenium brachytherapy for retinoblastoma. Int J Radiat Oncol Biol Phys. 2008;71(3):821–828.
9. Merchant TE, Gould CJ, Wilson MW, Hilton NE, Rodrigue-Galindo C, Haik BG. Episcleral plaque brachytherapy for retinoblastoma. Pediatr Blood Cancer. 2004;43(2):134–138.
10. Amendola BE, Markoe AM, Augburger JJ, et al. Analysis of treatment results in 36 children with retinoblastoma treated by scleral plaque irradiation. Int J Radiat Oncol Biol Phys. 1999;17(3):657–670.
11. Shields CL, Shields JA, Cather J, Othmane I, Singh AD, Micaily B. Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology. 2001;108(11):2116–2121.
12. Munier FL, Beck-Popovic M, Pantal SS. Palladium-103 for choroidal Melanoma Study Group. Risk factors for cataract after palladium-103 episcleral plaque radiotherapy. Int J Radiat Oncol Biol Phys. 2011;80(3):800–806.
13. Flesey E, Trmkova P, van Rij C, et al. Improving organ-at-risk sparing for choroidal melanoma patients: a CT-based two-beam strategy in ocular proton therapy with a dedicated eyeliner. Radiother Oncol. 2022;171:173–181.
14. Chiu-Tsao ST, Azrahah MA, Finger PT, et al. Dosimetry of (125)I and (103)Pd COMS eye plaques for intracranial tumors: report of Task Group 129 by the AAPM and AAPS Med Phys. 2012;39(3):6161–6184.
15. Kivela T, Simpson ER, Grosniklaus HE, et al. Uveal melanoma. (Chapter 67). In: Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual. eighth ed. Springer International Publishing; 2016:827–839.
16. Zafar SN, Siddiqui SN, Zaheer N. Tumor regression patterns in retinoblastoma. J Pediatr Ophthalmol Strabismus. 2005;42(5):220–226.
17. Vassal SN, Siddiqui SN, Zaheer N. Tumor regression patterns in retinoblastoma. J Pediatr Ophthalmol Strabismus. 2005;42(5):220–226.
18. Kivela T, Simpson ER, Grosniklaus HE, et al. Uveal melanoma (Chapter 67). In: Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual. eighth ed. Springer International Publishing; 2016:827–839.
19. Flesey E, Trmkova P, van Rij C, et al. Improving organ-at-risk sparing for choroidal melanoma patients: a CT-based two-beam strategy in ocular proton therapy with a dedicated eyeliner. Radiother Oncol. 2022;171:173–181.
20. Chiu-Tsao ST, Azrahah MA, Finger PT, et al. Dosimetry of (125)I and (103)Pd COMS eye plaques for intracranial tumors: report of Task Group 129 by the AAPM and AAPS Med Phys. 2012;39(3):6161–6184.
21. Kivela T, Simpson ER, Grosniklaus HE, et al. Uveal melanoma (Chapter 67). In: Amin MB, Edge SB, Greene FL, et al., eds. AJCC Cancer Staging Manual. eighth ed. Springer International Publishing; 2016:827–839.